GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Capex-to-Operating-Cash-Flow

Dechra Pharmaceuticals (LSE:DPH) Capex-to-Operating-Cash-Flow : 1.38 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Dechra Pharmaceuticals's Capital Expenditure for the six months ended in Jun. 2023 was £-16.70 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2023 was £12.10 Mil.

Hence, Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow for the six months ended in Jun. 2023 was 1.38.


Dechra Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Capex-to-Operating-Cash-Flow Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.46 1.51 0.63 0.48

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.56 0.81 0.26 1.38

Competitive Comparison of Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.



Dechra Pharmaceuticals Capex-to-Operating-Cash-Flow Calculation

Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-30.3) / 63.6
=0.48

Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-16.7) / 12.1
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dechra Pharmaceuticals  (LSE:DPH) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Dechra Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines